What is Eyevensys?
Founded in 2008, Eyevensys operates at the intersection of advanced biotechnology and ophthalmology. The company specializes in developing innovative technologies designed to enable the sustained, localized production of therapeutic proteins within the eye. By addressing the limitations of traditional delivery methods, Eyevensys aims to provide more effective, long-term treatment options for a broad spectrum of ophthalmic diseases. Its position as a clinical-stage entity highlights its transition from foundational research to rigorous human trials, marking a critical phase in its commercialization roadmap.
How much funding has Eyevensys raised?
Eyevensys has raised a total of $43.7M across 3 funding rounds:
Series A
$1.7M
Series B
$30M
Series B
$12M
Series A (2016): $1.7M with participation from Pontifax
Series B (2020): $30M, investors not publicly disclosed
Series B (2021): $12M supported by Korea Investment Holdings
Key Investors in Eyevensys
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages.
Korea Investment Holdings
A major financial firm and institutional investor specializing in asset management, securities brokerage, and investment banking within the Korean market.
What's next for Eyevensys?
With the recent strategic investment, Eyevensys is well-positioned to accelerate its clinical development programs and refine its proprietary delivery technology. The company is expected to prioritize the advancement of its lead candidates through the regulatory pipeline, aiming to demonstrate clinical efficacy and safety in target patient populations. As the firm scales its operations, the focus will likely shift toward establishing strategic partnerships and preparing for potential market entry, leveraging its unique intellectual property to address significant unmet needs in the global eye care market.
See full Eyevensys company page
